In Hindsight, Savara Wishes It Led With Patient-Reported Secondary Endpoint For Molgradex

 
• By Joseph Haas
  
human-lungs
Savara specializes in orphan lung disease indications
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D